<DOC>
	<DOCNO>NCT01363713</DOCNO>
	<brief_summary>Safety efficacy DE-114 ophthalmic solution evaluate patient allergic conjunctivitis , open-label , multicenter study .</brief_summary>
	<brief_title>A Long-term Study DE-114 Ophthalmic Solution Patients With Allergic Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Provided sign , write informed consent . Has positive result Type I allergy test . If subject female childbearing potential , must utilize reliable contraceptive throughout study , must negative urine pregnancy test prior enrollment study . Females pregnant , nurse planning pregnancy , females childbearing potential use reliable method contraception . Presence abnormality significant illness could expect interfere study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>